Patient dies in Pfizer Hemophilia drug study
The therapy, a once-a-week injection, gained U.S. approval last year to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older by targeting blood-clotting proteins. Pfizer does not anticipate any impact to safety for …